These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

857 related articles for article (PubMed ID: 28280301)

  • 21. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy.
    Mendell JR; Goemans N; Lowes LP; Alfano LN; Berry K; Shao J; Kaye EM; Mercuri E;
    Ann Neurol; 2016 Feb; 79(2):257-71. PubMed ID: 26573217
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Eteplirsen Treatment for Duchenne Muscular Dystrophy: A Qualitative Patient Experience Study.
    Iff J; Carmichael C; McKee S; Sehinovych I; McNeill C; Tesi-Rocha C; Henricson E; Muntoni F; Kitchen H
    Adv Ther; 2024 Aug; 41(8):3278-3298. PubMed ID: 38958840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Survival among patients receiving eteplirsen for up to 8 years for the treatment of Duchenne muscular dystrophy and contextualization with natural history controls.
    Iff J; Done N; Tuttle E; Zhong Y; Wei F; Darras BT; McDonald CM; Mercuri E; Muntoni F
    Muscle Nerve; 2024 Jul; 70(1):60-70. PubMed ID: 38482981
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis.
    Shimizu-Motohashi Y; Murakami T; Kimura E; Komaki H; Watanabe N
    Orphanet J Rare Dis; 2018 Jun; 13(1):93. PubMed ID: 29907124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Casimersen for Duchenne muscular dystrophy.
    Wilton-Clark H; Yokota T
    Drugs Today (Barc); 2021 Dec; 57(12):707-717. PubMed ID: 34909800
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Toxicological Characterization of Exon Skipping Phosphorodiamidate Morpholino Oligomers (PMOs) in Non-human Primates.
    Carver MP; Charleston JS; Shanks C; Zhang J; Mense M; Sharma AK; Kaur H; Sazani P
    J Neuromuscul Dis; 2016 Aug; 3(3):381-393. PubMed ID: 27854228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Patients organizations and new drug approval in the US. Eteplirsen and Duchenne muscular dystrophy case].
    Dal-Ré R; Lopez de Munain A; Ayuso C
    Rev Neurol; 2017 Oct; 65(8):373-380. PubMed ID: 28990648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy.
    Alfano LN; Charleston JS; Connolly AM; Cripe L; Donoghue C; Dracker R; Dworzak J; Eliopoulos H; Frank DE; Lewis S; Lucas K; Lynch J; Milici AJ; Flynt A; Naughton E; Rodino-Klapac LR; Sahenk Z; Schnell FJ; Young GD; Mendell JR; Lowes LP
    Medicine (Baltimore); 2019 Jun; 98(26):e15858. PubMed ID: 31261494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga.
    Aartsma-Rus A; Krieg AM
    Nucleic Acid Ther; 2017 Feb; 27(1):1-3. PubMed ID: 27929755
    [No Abstract]   [Full Text] [Related]  

  • 30. A Sequel to the Eteplirsen Saga: Eteplirsen Is Approved in the United States but Was Not Approved in Europe.
    Aartsma-Rus A; Goemans N
    Nucleic Acid Ther; 2019 Feb; 29(1):13-15. PubMed ID: 30526286
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimizing antisense oligonucleotides using phosphorodiamidate morpholino oligomers.
    Popplewell LJ; Malerba A; Dickson G
    Methods Mol Biol; 2012; 867():143-67. PubMed ID: 22454060
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Viltolarsen: From Preclinical Studies to FDA Approval.
    Roshmi RR; Yokota T
    Methods Mol Biol; 2023; 2587():31-41. PubMed ID: 36401022
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Shorter Phosphorodiamidate Morpholino Splice-Switching Oligonucleotides May Increase Exon-Skipping Efficacy in DMD.
    Akpulat U; Wang H; Becker K; Contreras A; Partridge TA; Novak JS; Cirak S
    Mol Ther Nucleic Acids; 2018 Dec; 13():534-542. PubMed ID: 30396145
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Eteplirsen (Exondys 51) for duchenne muscular dystrophy.
    Med Lett Drugs Ther; 2016 Nov; 58(1507):145-146. PubMed ID: 27805575
    [No Abstract]   [Full Text] [Related]  

  • 35. Long-term systemic administration of unconjugated morpholino oligomers for therapeutic expression of dystrophin by exon skipping in skeletal muscle: implications for cardiac muscle integrity.
    Malerba A; Boldrin L; Dickson G
    Nucleic Acid Ther; 2011 Aug; 21(4):293-8. PubMed ID: 21851223
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An Overview of Recent Therapeutics Advances for Duchenne Muscular Dystrophy.
    Mah JK
    Methods Mol Biol; 2018; 1687():3-17. PubMed ID: 29067652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systemic Injection of Peptide-PMOs into Humanized DMD Mice and Evaluation by RT-PCR and ELISA.
    Melo D; Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1828():263-273. PubMed ID: 30171547
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exon Skipping Therapy.
    Young CS; Pyle AD
    Cell; 2016 Nov; 167(5):1144. PubMed ID: 27863231
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 2'-O-Methyl RNA/Ethylene-Bridged Nucleic Acid Chimera Antisense Oligonucleotides to Induce Dystrophin Exon 45 Skipping.
    Lee T; Awano H; Yagi M; Matsumoto M; Watanabe N; Goda R; Koizumi M; Takeshima Y; Matsuo M
    Genes (Basel); 2017 Feb; 8(2):. PubMed ID: 28208626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exon-skipping events in candidates for clinical trials of morpholino.
    Nakano S; Ozasa S; Yoshioka K; Fujii I; Mitsui K; Nomura K; Kosuge H; Endo F; Matsukura M; Kimura S
    Pediatr Int; 2011 Aug; 53(4):524-9. PubMed ID: 21342350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.